Decoy Biosystems

Decoy Biosystems is a biotechnology company dedicated to cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas, which account for approximately 90% of all cancer deaths. Currently, the company has developed a novel cancer immunotherapy based on multi-Toll-like receptor (TLR) agonists.